Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Research

DNA Damage & Repair

DNA Damage & Repair

Genome Integrity & Epigenetics

Genome Integrity & Epigenetics

Immunology

Immunology

Metabolism

Metabolism

Translational Research

Translational Research

Tumour Microenvironment

Tumour Microenvironment

Delivering the right treatment to the right patient at the right time.

Adjuvant Colorectal Cancer

Our work focuses on the application of novel imaging modalities and on the development of radiation delivery methods. Both of these are dependent on a range of interrelated technologies.

Advanced Technology Development

The aim of our research is to design and develop innovative cancer killing viruses and oncolytic vaccines.

Anticancer Viruses and Cancer Vaccines

Our major interests are in the fundamental genetics and biology of colorectal cancer and their potential applications; and the characterisation and population distribution of genetic diversity in human populations, especially of the British Isles.

Cancer and Immunogenetics

Research in this group focusses on the mechanisms that give rise to the abnormal proliferation characteristic of tumour cells.

Cancer Cell Cycle

Investigating post-transcriptional mechanisms that drive cancer behaviour and researching novel cancer therapeutics for patients with advanced malignancies.

Cancer Therapeutics and mRNA Dysregulation

A major focus of our work is exploring how ATRX prevents normal cells from elongating their telomeres via the ALT pathway and trying to understand the role of ATRX in DNA replication and repair.

Cancer Therapeutics, DNA Damage & Repair

Our group objective is to understand the role of the ubiquitin system in cancer cell survival and response to radiation treatment. Further investigation in this process will prove to be a powerful tool for the design and implementation of novel cancer treatments

Cell Cycle and Ubiquitin Signalling

Our research aims to understand the cell and molecular biology behind frequent tumour mutations and how they influence cancer onset and/or therapy.

Cell Signalling

The aim of our research is to understand how genome stability is maintained in response to DNA double-strand breaks, and to exploit our findings to target cancer.

Chromosome Integrity

We use system biology approaches to search for integrated genomic blueprints that enable us to understand and predict how cancer will evolve and respond to treatment.

Computational Biology and Integrative Genomics

We study the signalling mechanisms cells use to respond to DNA damage and why defects in these pathways cause human diseases such as cancer.

DNA Damage & Disease

We are interested in the role of the ubiquitin-proteasome system in DNA repair, ageing, cancer and radiotherapy.

DNA Damage Response

We are investigating DNA damage signalling and repair factors in bladder cancer to develop new radiotherapy-based treatments and to identify markers to select the most suitable treatments for individual patients.

DNA Repair in Cancer Treatment

Our research concentrates on development of new cancer drugs and on the treatment of melanoma.

Early Phase Clinical Trials & Melanoma Therapy

Our goals are to identify the role of the inflammatory and metabolic microenvironment in brain metastasis, and to develop imaging biomarkers for tumour detection and monitoring.

Experimental Neuroimaging

Our research is focused on gaining a greater understanding of how homologous recombination (HR), the major DNA repair pathway in mammalian cells, helps to prevent genomic instability, the underlying mechanism of many cancers. In particular, we study how tumor cells lacking BRCA1 or BRCA2 gene function differ from normal cells in their responses to exogenous damage induced by ionizing radiation, as well as to cell-intrinsic challenges that arise during DNA replication.

Genome Stability and Tumourigenesis

We are interested in the genetic and epigenetic determinants of inter-individual variation in immune responses.

Genomics of Inflammation and Cancer Immunology

The focus of the group is on tumour angiogenesis and the role of notch signalling, and hypoxia biology and its regulation.

Hypoxia and Angiogenesis

We are studying the role of insulin-like growth factor (IGF) signalling in tumour biology, aiming to use this information to develop new ways to prevent and treat cancer.

Insulin-like Growth Factor

Our group aims to identify novel therapies that target subgroups of lung cancer patients harbouring specific genetic changes.

Lung Cancer Research

We are interested in the mechanisms underlying the development of metastasis, the spread of cancer from one part of the body to another.

Mechanisms of Metastasis

Our research links basic science with clinical applications and focuses on understanding the mechanisms behind tumour resistance to radiation.

Molecular Resistance to Treatments

Personalising gastro-intestinal cancers radiotherapy: the ultimate aim of the research of my group is to maximise clinical benefit in terms of better tumour control and reduction in toxicity after radiotherapy to enhance life expectancy of the patients.

New Technical Radiotherapy/Advanced Radiation Oncology

Our group focuses on using imaging techniques in small-scale trials with the particular ambitions of improving the mechanisms of data analysis and correlating the imaging data provided with histology and treatment outcomes.

Novel Clinical Imaging Research

Our research is interdisciplinary, focusing on nucleic acid chemistry and its applications in other fields including DNA diagnostics, forensic science and nanotechnology.

Nucleic Acids

We develop image analysis methods for quantitative analysis of medical images, specifically for a range of applications in cancer.

Oncological Image Analysis

The aim of our research is to identify molecular-based disease classifiers using clinical omics to underpin precision medicine approaches to be used for the selection of patients for the appropriate therapy.

Oxford Molecular Diagnostics

Our research group specialises in bringing fundamental physical concepts to enhance everyday clinical practice.

Radiation Therapy Medical Physics

We aim to develop new radioisotope-labelled compounds for the imaging of tumour biology.

Radiopharmaceuticals and Molecular Imaging

Personalising radiotherapy using functional imaging: we apply functional and molecular imaging techniques to developing radiotherapy personalised to each patients’ individual tumour biology.

Radiotherapeutics & Radioimaging

We are investigating how tumours survive in conditions which include low oxygen (hypoxia). Our goal is to target the hypoxic parts of tumours to improve cancer therapy.

Tumour Hypoxia

Our research focuses on finding new ways of making tumours more sensitive to radiotherapy treatment.

Tumour Radiosensitivity

Supporting academic research within and outside of the university, we provide specialist analytical chemistry support in the majority through HPLC-MS or HPLC-MS-MS techniques with additional UV-visible absorbance and fluorescence detection abilities.

Bioanalysis

We provide expertise in computational biology ranging from applied statistics to computational and functional genomics.

Bioinformatics

The Early Phase Clinical Trials Unit (EPCTU) aims to support the translation of research findings in to clinical practice.

Early Phase Clinical Trials Unit

Flow cytometry determines the 'what', the 'where' and the 'how much' of material in cells, and is an important step in testing effects of drug interventions.

Flow Cytometry

The Live Tissue Facility is designed to boost the translational impact of oncological research without users having to independently create ethics applications and collection logistics.

Live Tissue Facility

The Mechanical Workshop delivers an on-site fabrication facility for custom-made, precision mechanical items for use in scientific research.

Mechanical Workshop

The Microscopy SRF aims to provide research groups with imaging technologies to investigate cellular processes both in vitro and in vivo.

Microscopy

The Oncology Clinical Trials Office (OCTO) provides clinical trial management support to investigators across the CRUK Oxford Centre to manage trials from concept to completion.

Oncology Clinical Trials Office (OCTO)

The PET Radiochemistry and Radiopharmacy core supports radiochemistry-dependent research programmes and provide GMP-grade PET radiopharmaceuticals for clinical trials.

PET Radiochemistry and Radiopharmacy (PROx)

The Imaging SRF provides routine technical support services and operates a programme of advanced method development in order to optimise the use of the imaging facility.

Pre-Clinical Imaging

Proteomics studies proteins on a large scale. Proteins are vital to living organisms and their multi-functional characteristics act as potential targets for drug therapies. Therefore, proteomics can be used for biomarker and target discovery, drug profiling and target validation.

Proteomics

The Radiation Biophysics Facility develops and supports a unique range of radiation resources and techniques along with providing associated expertise.

Radiation Biophysics

Translational Histopathology

Translational Histopathology

Key Research Links

Latest Research News

ATOMs of Chocolate

29 March 2019

On Sat 23 March, four members of the Department of Oncology set out bars of chocolate on a table in the Market Square in Abingdon. Our aim? To introduce passers-by to some key concepts in radiotherapy.

New 'molecular fibres' may help cells repair DNA

25 March 2019

Research by the DNA Damage & Disease research group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

Study suggests immune system plays key role in survival after pancreatic cancer surgery

12 February 2019

Researchers in Oxford have found that an individual’s immune system – and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.

More news